Volition announces u.s. clinical study for nets

Henderson, nev. , aug. 10, 2022 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, has announced a sponsored research agreement with the university of texas md anderson cancer center to evaluate the role of neutrophil extracellular traps ("nets") in cancer patients with sepsis.

VNRX Ratings Summary

VNRX Quant Ranking